文献速递呼吸道感染呼吸危重症与机械通气

辅助性糖皮质激素与非HIV肺孢子菌肺炎临床结局

Adjunctive Corticosteroid Use and Clinical Outcomes in Non-HIV Pneumocystis jirovecii Pneumonia.
PubMed 文献 · Chest · 2025-11-07

该多中心回顾性队列纳入375例需吸氧的非HIV免疫抑制肺孢子菌肺炎成人,采用边际结构模型分析21天内累积激素剂量与结局的关系。结果显示更高的累积激素剂量与90天死亡风险增加相关,未改善插管或呼吸支持脱离。

要点

  • 非HIV肺孢子菌肺炎患者中,更高累积激素剂量与90天死亡风险增加相关。
  • 激素暴露与插管风险或更快脱离高级呼吸支持无显著关联。
  • 超过试验验证方案的激素剂量应谨慎使用。

核心结论

  • 在伴低氧血症的非HIV肺孢子菌肺炎患者中,更高累积糖皮质激素暴露与90天死亡风险增加相关,且未改善呼吸结局。

研究设计与样本

  • 多中心回顾性队列分析,纳入2019至2025年间住院的375例非HIV免疫抑制成人肺孢子菌肺炎患者,所有患者治疗开始时存在低氧血症。
  • 激素暴露建模为21天内连续累积时变剂量,采用边际结构模型及逆概率治疗加权调整基线协变量和时变疾病严重度。

主要发现

  • 375例中351例(93.6%)接受糖皮质激素。
  • 免疫抑制最常见原因为血液恶性肿瘤(30%)、实体瘤化疗(30%)、自身免疫病(17%)和实体器官移植(14%)。
  • 56%患者需ICU入住,44%患者在90天内死亡。
  • 激素暴露与插管风险(HR 0.99;95%CI 0.97-1.02)或更快脱离高级呼吸支持(HR 1.00;95%CI 0.98-1.02)无显著关联。

临床怎么用

  • 对非HIV肺孢子菌肺炎伴低氧血症患者,应审慎评估辅助性糖皮质激素的累积剂量,避免超过试验验证方案的高剂量暴露。
  • 临床决策中需权衡激素的潜在获益与累积剂量相关的死亡风险增加。

局限性

  • 回顾性队列设计可能存在残余混杂。
  • 研究仅纳入需要吸氧的低氧血症患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjunctive corticosteroids improve outcomes in HIV-associated Pneumocystis jirovecii pneumonia (PCP), but their role in non-HIV-associated PCP is uncertain. Prior evidence largely has been limited to binary treatment groups and rarely has accounted for daily or cumulative dose effects. RESEARCH QUESTION: What is the dose-response relationship between adjunctive corticosteroids and outcomes in non-HIV immunocompromised adults with PCP requiring supplemental oxygen? METHODS: We conducted a multicenter retrospective cohort analysis of 375 non-HIV immunocompromised adults with proven or probable PCP hospitalized between 2019 and 2025. All patients were hypoxemic at treatment initiation. Corticosteroid exposure was modeled as a continuous, cumulative time-varying dose over 21 days using marginal structural models with inverse probability of treatment weighting to adjust for baseline covariates and time-varying illness severity. RESULTS: Of 375 patients, 351 patients (93.6%) received corticosteroids. The most common causes of immunosuppression were hematologic malignancy (30%), solid tumors on chemotherapy (30%), autoimmune disease (17%), and solid organ transplantation (14%); 56% of patients required ICU admission and 44% of patients died within 90 days. Greater cumulative steroid dose was associated with increased risk of 90-day mortality (weighted hazard ratio [HR], 1.01 per 100 mg prednisone-equivalent; 95% CI, 1.00-1.02; P = .006). Steroid exposure was not associated with risk of intubation (HR, 0.99; 95% CI, 0.97-1.02) or faster liberation from advanced respiratory support (HR, 1.00; 95% CI, 0.98-1.02). INTERPRETATION: In patients with non-HIV PCP with hypoxemia, higher cumulative corticosteroid exposure was not associated with improved respiratory outcomes and was linked to increased mortality. Use of doses exceeding trial-tested regimens should be approached with caution.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Pulsipher AM, Vikram HR, Gotway MB, et al. Adjunctive Corticosteroid Use and Clinical Outcomes in Non-HIV Pneumocystis jirovecii Pneumonia. Chest. 2025. PMID: 41205908. doi:10.1016/j.chest.2025.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。